Results 141 to 150 of about 5,084 (185)

Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma. [PDF]

Med
Karapetyan L, Xu J, Ward K, Kalos D, Schachner B, Ali J, Song X, Kuriakose J, Hall MS, Chau J, Cox CA, Al-Bzour AN, Falahat R, Perez MC, Mullinax JE, Zager JS, Gonzalez R, Sondak VK, Tsai KY, Messina JL, Moran-Segura C, Lopez-Blanco N, Alleyne AE, Nguyen JV, Schell MJ, Markowitz J, Brohl AS, Eroglu Z, Tarhini AA, Khushalani NI, Hwu P, Mulé JJ, Sarnaik AA, Beatty MS, Pilon-Thomas S.   +34 more
europepmc   +1 more source

Advances in Immune Checkpoint Inhibitors for Cancer Treatment. [PDF]

Cancers (Basel)
Chen K, Zhu F, Li X, Yoshimura T.
europepmc   +1 more source

Lymphocyte activation gene 3 in autoimmune disease: from molecular mechanisms to clinical applications. [PDF]

Front Immunol
Guo L, Pan L, Liu C, Yang S.
europepmc   +1 more source

CD160-Derived Peptide as a Bidirectional Inhibitor Toward Immune Checkpoints BTLA/HVEM and HVEM/LIGHT. [PDF]

J Med Chem
Lipińska M, Ciura P, Gumpelmair S, Sikorska E, Kuncewicz K, Sieradzan AK, Steinberger P, Wardowska A, Spodzieja M.   +8 more
europepmc   +1 more source

miR-155-5p Silencing Does Not Alter BTLA Molecule Expression in CLL T Cells: Implications for Targeted Immunotherapy. [PDF]

Biomolecules
Kosmaczewska A, Ciszak L, Andrzejczak A, Tomkiewicz A, Partyka A, Rojek-Gajda Z, Frydecka I, Wołowiec D, Wróbel T, Bojarska-Junak A, Roliński J, Karabon L.   +11 more
europepmc   +1 more source

PTPN6/SHP-1 in autoimmune disease: immune tolerance, regulatory mechanisms, and therapeutic targeting. [PDF]

Front Immunol
Chang RC, Lasalle C, Wang Y, Markovics A, Amber KT, Mansini AP.   +5 more
europepmc   +1 more source

The DC1 conundrum: Do type I dendritic cells make or break allograft tolerance? [PDF]

Am J Transplant
Shen IR, Jeyamogan S, Jones RTL, Mathew JM, Thorp EB, Davidson JT.   +5 more
europepmc   +1 more source

Modulation of the PD-1/PD-L1 axis and tumor immunity by metals and metalloids: mechanistic insights and human health implications. [PDF]

Front Immunol
Lu Z, Chen G, Qiu J, Huo X, Xu X.
europepmc   +1 more source

An immune exhaustion signature predicts prognosis and identifies patients with diffuse large B-cell lymphoma (DLBCL) who derive preferential benefit from chimeric antigen receptor (CAR)-T cell therapy. [PDF]

Cancer Pathog Ther
Zheng B, Hu W, Fang Y, Li R.
europepmc   +1 more source

Comprehensive genomics and functional analyses identify <i>SMARCAL1</i> as a key oncogenic regulator in lung adenocarcinoma. [PDF]

Transl Cancer Res
Huang Z, Li Y, He J, Xu Z, Peng H, Yang N.   +5 more
europepmc   +1 more source